arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

AGIOS PHARMACEUTICALS, INC.

AGIO
$34.18 ▼ -0.80 (-2.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

AGIOS PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.0B
Dividend Yield —
Revenue Growth 259.3% ↗
Op. Margin -247.1%
ROIC -8.5% ↘
FCF / Share $-0.98 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.74M
↑ +259.3% —
Net Income Profit after all expenses
$-99.11M
↓ -11.0% —
Operating Margin Operating profit as % of sales
-247.1%
↓ -560.8% —
FCF / Share Free cash flow per share
$-0.98
↑ +51.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 59 quarters